
## Tae Hyun Kang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6140376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 604-609.	7.1	146
2	Revisiting the Role of Glycosylation in the Structure of Human IgG Fc. ACS Chemical Biology, 2012, 7, 1596-1602.	3.4	128
3	IgG Fc domains that bind C1q but not effector Fc $\hat{i}^3$ receptors delineate the importance of complement-mediated effector functions. Nature Immunology, 2017, 18, 889-898.	14.5	122
4	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nature Medicine, 2016, 22, 1465-1469.	30.7	104
5	Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Current Opinion in Biotechnology, 2011, 22, 858-867.	6.6	88
6	Boosting therapeutic potency of antibodies by taming Fc domain functions. Experimental and Molecular Medicine, 2019, 51, 1-9.	7.7	77
7	Protein Solubility and Folding Enhancement by Interaction with RNA. PLoS ONE, 2008, 3, e2677.	2.5	63
8	Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity. ACS Chemical Biology, 2013, 8, 368-375.	3.4	61
9	IgCA: A "Cross-Isotype―Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions. Chemistry and Biology, 2014, 21, 1603-1609.	6.0	55
10	An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. Nature Communications, 2019, 10, 5031.	12.8	49
11	Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms. Frontiers in Microbiology, 2020, 11, 1927.	3.5	43
12	Farewell to Animal Testing: Innovations on Human Intestinal Microphysiological Systems. Micromachines, 2016, 7, 107.	2.9	24
13	An Engineered Human Fc variant With Exquisite Selectivity for FcÎ <sup>3</sup> RIIIaV158 Reveals That Ligation of FcÎ <sup>3</sup> RIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages. Frontiers in Immunology, 2019, 10, 562.	4.8	17
14	Efficient expression and purification of human aglycosylated Fcl <sup>3</sup> receptors in <i>Escherichia coli</i> . Biotechnology and Bioengineering, 2010, 107, 21-30.	3.3	15
15	Computerâ€based engineering of thermostabilized antibody fragments. AICHE Journal, 2020, 66, e16864.	3.6	12
16	Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding. Biotechnology and Bioprocess Engineering, 2014, 19, 780-789.	2.6	11
17	Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer. Biomolecules, 2020, 10, 382.	4.0	8
18	Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic. International Journal of Molecular Sciences, 2021, 22, 9489.	4.1	4